149 related articles for article (PubMed ID: 37962843)
1. Higher PD-1/Tim-3 expression on IFN-γ+ T cells is associated with poor prognosis in patients with acute myeloid leukemia.
Huang S; Zhao Y; Lai W; Tan J; Zheng X; Zha X; Li Y; Chen S
Cancer Biol Ther; 2023 Dec; 24(1):2278229. PubMed ID: 37962843
[TBL] [Abstract][Full Text] [Related]
2. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 expression in T cells from patients with acute myeloid leukemia.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Zha X; Li Y; Chen S
Cytometry B Clin Cytom; 2022 Mar; 102(2):143-152. PubMed ID: 34913594
[TBL] [Abstract][Full Text] [Related]
3. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract][Full Text] [Related]
4. Increased exhausted CD8
Tan J; Chen S; Huang J; Chen Y; Yang L; Wang C; Zhong J; Lu Y; Wang L; Zhu K; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e266-e274. PubMed ID: 29943497
[TBL] [Abstract][Full Text] [Related]
5. Tim-3 and PD-1 blocking cannot restore the functional properties of natural killer cells in early clinical stages of chronic lymphocytic leukemia: An
Astaneh M; Rezazadeh H; Hossein-Nataj H; Shekarriz R; Zaboli E; Shabani M; Asgarian-Omran H
J Cancer Res Ther; 2022; 18(3):704-711. PubMed ID: 35900543
[TBL] [Abstract][Full Text] [Related]
6. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia.
Zhou Q; Munger ME; Veenstra RG; Weigel BJ; Hirashima M; Munn DH; Murphy WJ; Azuma M; Anderson AC; Kuchroo VK; Blazar BR
Blood; 2011 Apr; 117(17):4501-10. PubMed ID: 21385853
[TBL] [Abstract][Full Text] [Related]
7. Combined Immune Checkpoint Blockade Enhances Antiviral Immunity against Bovine Leukemia Virus.
Nakamura H; Konnai S; Okagawa T; Maekawa N; Sajiki Y; Watari K; Kamitani K; Saito M; Kato Y; Suzuki Y; Murata S; Ohashi K
J Virol; 2023 Jan; 97(1):e0143022. PubMed ID: 36598199
[TBL] [Abstract][Full Text] [Related]
8. Increased TOX expression concurrent with PD-1, Tim-3, and CD244 in T cells from patients with non-Hodgkin lymphoma.
Huang S; Liang C; Zhao Y; Deng T; Tan J; Lu Y; Liu S; Li Y; Chen S
Asia Pac J Clin Oncol; 2022 Feb; 18(1):143-149. PubMed ID: 33608984
[TBL] [Abstract][Full Text] [Related]
9. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
[TBL] [Abstract][Full Text] [Related]
10. Combined TIM-3 and PD-1 blockade restrains hepatocellular carcinoma development by facilitating CD4+ and CD8+ T cell-mediated antitumor immune responses.
Zhang XS; Zhou HC; Wei P; Chen L; Ma WH; Ding L; Liang SC; Chen BD
World J Gastrointest Oncol; 2023 Dec; 15(12):2138-2149. PubMed ID: 38173440
[TBL] [Abstract][Full Text] [Related]
11. BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia.
Zhong M; Gao R; Zhao R; Huang Y; Chen C; Li K; Yu X; Nie D; Chen Z; Liu X; Liu Z; Chen S; Lu Y; Yu Z; Wang L; Li P; Zeng C; Li Y
Cell Death Dis; 2022 Aug; 13(8):671. PubMed ID: 35918330
[TBL] [Abstract][Full Text] [Related]
12. Increasing Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with acute myeloid leukemia.
Tan J; Huang S; Huang J; Yu Z; Chen Y; Lu Y; Li Y; Chen S
Asia Pac J Clin Oncol; 2020 Jun; 16(3):137-141. PubMed ID: 32030888
[TBL] [Abstract][Full Text] [Related]
13. PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation.
Kong Y; Zhang J; Claxton DF; Ehmann WC; Rybka WB; Zhu L; Zeng H; Schell TD; Zheng H
Blood Cancer J; 2015 Jul; 5(7):e330. PubMed ID: 26230954
[TBL] [Abstract][Full Text] [Related]
14. Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy.
Dama P; Tang M; Fulton N; Kline J; Liu H
J Immunother Cancer; 2019 Jul; 7(1):175. PubMed ID: 31291985
[TBL] [Abstract][Full Text] [Related]
15. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.
Tan J; Yu Z; Huang J; Chen Y; Huang S; Yao D; Xu L; Lu Y; Chen S; Li Y
Biomark Res; 2020; 8():6. PubMed ID: 32082573
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia.
Chajuwan T; Kansuwan P; Kobbuaklee S; Chanswangphuwana C
Leuk Lymphoma; 2022 Feb; 63(2):450-456. PubMed ID: 34585994
[TBL] [Abstract][Full Text] [Related]
17. CD8
Wang M; Bu J; Zhou M; Sido J; Lin Y; Liu G; Lin Q; Xu X; Leavenworth JW; Shen E
Clin Immunol; 2018 May; 190():64-73. PubMed ID: 28893624
[TBL] [Abstract][Full Text] [Related]
18. Blockade of PD-1 and TIM-3 immune checkpoints fails to restore the function of exhausted CD8
Rezazadeh H; Astaneh M; Tehrani M; Hossein-Nataj H; Zaboli E; Shekarriz R; Asgarian-Omran H
Immunol Res; 2020 Oct; 68(5):269-279. PubMed ID: 32710227
[TBL] [Abstract][Full Text] [Related]
19. [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients].
Ge MJ; Xu KL; Xu T; Tang YN; Li ZY; Yan ZL; Sun HY; Cheng H; Zhu F; Sang W; Huang YH; Qiu TT; Li DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):748-752. PubMed ID: 32552931
[TBL] [Abstract][Full Text] [Related]
20. Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity.
Rahimi A; Hossein-Nataj H; Hajheydari Z; Aryanian Z; Shayannia A; Ajami A; Asgarian-Omran H
Exp Dermatol; 2019 Jun; 28(6):674-681. PubMed ID: 31046170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
